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The role of increased sympathetic nervous system
(SNS) activity in the pathogenesis of obesity
hypertension and insulin resistance is controver-
sial. Eight dogs were instrumented and fed a
high-fat diet (HFD) for 6 weeks. Dogs were
evaluated for changes in weight, blood pressure,
insulin resistance, and norepinephrine (NE) kinet-
ics using a two-compartment model. The HFD
resulted in weight gain, hypertension, and insulin
resistance. During the 6 weeks of the HFD,
although plasma NE concentration trended
toward increasing (P=.09), SNS, assessed by NE
kinetic studies, significantly increased (P=.009).
Within 1 week of starting the HFD, NE release
into the extravascular compartment (NE2)
increased from 3.440.59 lg ⁄ mL to
4.870.80 lg ⁄ mL (P<.01) and this increase was
maintained over the next 5 weeks of the HFD
(NE2 at week 6 was 4.660.97 lg ⁄ mL). In
addition to the increased NE2 there was also a
significant increase in NE clearance (P=.04).
There were significant correlations between the
increase in NE2 and both the development of
insulin resistance and hypertension. This study
supports the hypothesis that activation of the
SNS plays a pivotal role in the metabolic and
hemodynamic changes that occur with weight
gain induced by HFD. J Clin Hypertens
(Greenwich). 2010;12:117–124. ª2009 Wiley
Periodicals, Inc.
The sympathetic nervous system (SNS) playsan important role in metabolic homeostasis.
Landsberg and Young1 reported that short-term
overfeeding of rats activated the SNS. These and
other observations led Landsberg2 to hypothesize
that the increase in SNS activity with weight gain
serves the homeostatic role of stimulating thermo-
genesis to prevent further weight gain. In an
attempt to test this hypothesis there has been con-
siderable controversy regarding the effects of obes-
ity on SNS activation. Data from a review of more
than 40 different studies suggests that whole body
SNS activity, measured by plasma norepinephrine
(NE) concentration, urinary NE excretion, and sys-
temic NE spillover rate into the plasma, is either the
same in lean and obese persons or increases
with increasing obesity.3 Masuo and colleagues4,5
reported that plasma NE concentrations not only
increased following weight gain in Japanese men
but plasma NE also appeared to predict subsequent
weight gain and blood pressure (BP) elevation.
From the Department of Pediatrics, Pediatric
Cardiology Division1 and the Department of Internal
Medicine, Geriatrics Division,2 University of Michigan,
Ann Arbor, MI; and the Department of Internal
Medicine, Geriatrics Division, and Center on Aging,
University of Utah, Salt Lake City, UT;3 and the
Department of Veterans Affairs Salt Lake City
Geriatric Research, Education and Clinical Center, Salt
Lake City, UT4
Address for correspondence:
Albert P. Rocchini, MD, University of Michigan
Health System, L1242 Women’s, SPC 5204, 1500 East
Medical Center Drive, Ann Arbor, MI 48109-5204
E-mail rocchini@umich.edu
doi: 10.1111/j.1751-7176.2009.00230.x
VOL. 12 NO. 2 FEBRUARY 2010 THE JOURNAL OF CLINICAL HYPERTENSION 117
While Masuo’s findings from an observational,
cross-sectional study suggest that increases in
plasma NE concentrations occur with modest
weight gain, plasma NE concentrations are of lim-
ited value as a measure of sympathetic neural activ-
ity because they are influenced by the sampling site,
as well as by NE appearance and clearance from the
circulation.6
Clinical measurements of NE release from sym-
pathetic nerves to plasma and clinical measure-
ments of rates of sympathetic nerve firing by
clinical neurography provide the best methods for
assessing sympathetic nervous function in humans.7
Using isotope dilution methodology, regional heter-
ogeneity in SNS activity has been demonstrated in
obesity. Coppack and colleagues8 measured whole
body and regional (subcutaneous abdominal adi-
pose tissue and forearm) NE kinetics in lean and
obese women. Coppack found that although mean
systemic NE spillover tended to be higher in obese
than in lean persons, the differences were not statis-
tically significant, whereas adipose tissue and fore-
arm NE spillover rates were greater in lean than in
obese persons. Similarly, Vaz and colleagues9 dem-
onstrated that whole body plasma NE spillover
was unrelated to body mass index, whereas renal
NE spillover was significantly correlated with body
mass index and cardiac NE spillover was lower in
obese compared with lean persons.
Microneurography has also been used to directly
measure sympathetic neural activity in obese indi-
viduals. Most studies that measured muscle sympa-
thetic nerve activity have demonstrated higher nerve
activity in obese compared with lean individuals.10–13
However, Huggett and colleagues14 reported that
muscle sympathetic nerve activity was nearly identi-
cal in normal weight and overweight men, whereas
obese diabetic men had 50% higher muscle sympa-
thetic nerve activity.
One of the major limitations of all of these stud-
ies relating whole body SNS activation to obesity is
that they have been cross-sectional. There have
been few studies that have longitudinally evaluated
SNS activity in the same individual prior to and
after the development of obesity. Katzeff and col-
leagues15 measured the thermogenic and hormonal
responses to NE during overnutrition and undernu-
trition in 6 lean and 6 overweight male volunteers.
Although these investigators demonstrated that
overfeeding did not increase the thermogenetic
responses to NE, they did demonstrate that both
lean and obese individuals did increase their plasma
NE concentration with overfeeding. Gentile and
colleagues16 demonstrated that overfeeding 12 non-
obese male volunteers resulted in an increase in
muscle sympathetic neural activity and that the
change in muscle sympathetic nerve activity burst
frequency was correlated with the percent increase
in body weight, change in body fat, and percent
change in body fat. Gentile did not measure the
change in NE kinetics with overfeeding. In the cur-
rent study, we serially measured NE kinetic param-
eters before and after 1 and 6 weeks of feeding
dogs a high-fat diet in order to test the hypothesis
that weight gain results in altered whole body NE
kinetics.
METHODS
Eight adult mongrel dogs (5 males and 3 females)
were trained to stand quietly in a padded sling.
All dogs were then surgically instrumented with an
ascending aortic catheter and 2 right atrial catheters.
Surgical instrumentation of the animals was per-
formed under methohexital induction (12 mg ⁄kg)
and isoflurane (0.5–1.5%). After surgery, the dogs
were allowed to recover for 3 weeks before baseline
measurements were made. Dogs received a regular
diet (a diet that maintained weight constant), 1 to 2
cans of dog food (Ken-L-Ration; H. J. Heinz Com-
pany, Pittsburgh, PA), for 2 weeks followed by
6 weeks of a high-fat diet consisting of approxi-
mately 0.8 kg of cooked beef fat in addition to their
regular diet.17
In addition, all dogs received vitamin supplements
(VAL syrup; Fort Dodge Laboratories, Fort Dodge,
IA) and antibiotics throughout the entire study. The
dogs were housed in air-conditioned cages and were
fed between the hours of 1 pm and 3 pm each day.
BP, heart rate, and body weight were measured
daily. Plasma glucose and insulin were measured
twice a week during the entire study. NE kinetics
were measured before and after 1 and 6 weeks of the
high-fat diet in 7 of 8 dogs. In the other dog, the 1-
week post-fat measurements could not be made due
to catheter malfunction. All measurements were
made between 8 am and 11 am and before the daily
feeding (the dogs having not been fed since 5 pm the
previous day). The animals were housed and cared
for and all procedures in the study were in accor-
dance with National Institutes of Health guidelines
in addition to University of Michigan guidelines on
animal experimentation.
Laboratory Measurements
Arterial pressure was measured daily with a pres-
sure transducer mounted at the level of the heart.
BP signals were recorded and the analog signals
were sent to a computer to be analyzed. The
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computer calculated the average systolic, diastolic,
and mean BP and heart rate (over a 15- to 30-min-
ute period while the dog was resting quietly).
Insulin resistance was assessed by a single insulin
dose of 2 mU ⁄ (kgÆmin) by euglycemic hyperinsuli-
nemic clamp. The euglycemic hyperinsulinemic
clamp was performed in all dogs before starting the
high-fat diet and at 1 (day 8 or 9) and 6 weeks
(day 43 or 44) of the high-fat diet.18
NE kinetics was measured on the day before the
euglycemic clamp using 3H-NE. On the days that
NE kinetics was measured, the dogs were placed in
the padded sling for 30 minutes before starting
the measurements. 3H-NE (specific activity 40 to
60 Ci ⁄mmol; Perkin-Elmer, Norwalk, CT) was
given into the right atrial catheter as a continuous
infusion for 60 minutes at a rate of 0.013 lCi ⁄
(minÆkg). Arterial plasma samples were collected at
40, 50, and 60 minutes during 3H-NE infusion for
measurement of steady-state 3H-NE and plasma
NE concentrations. The 3H-NE infusion was then
stopped and blood samples were obtained at 1, 2,
4, 6, 8, 10, 12, 14, 16, 18, and 20 minutes after
discontinuing the infusion. The zero time value for
analysis of the disappearance curves was taken as
the mean of the 40-, 50-, and 60-minute samples.
Analytic Methods
Blood for serum glucose determination was drawn,
put in untreated polypropylene tubes, and centri-
fuged using an Eppendorf microcentrifuge (Brink-
man Instruments, Westbury, NY). The glucose
concentration of the supernatant was then mea-
sured in duplicate by the glucose oxidase method
using a glucose analyzer (model A23; Yellow
Springs Instruments, Yellow Spring, OH). Serum
insulin was measured by double-antibody radioim-
munoassay (ICN Biomedicals, Inc, Costa Mesa,
CA). Plasma electrolytes were measured by flame
photometry.
Blood samples for NE kinetics were collected
into chilled plastic tubes containing ethyleneglyco-
tetraacetic acid (EGTA) and reduced glutathione
and immediately placed on ice. They were
promptly centrifuged at 4C and the plasma was
stored at )70C. Plasma NE and epinephrine levels
were measured using single isotope assay, with all
samples from a given dog analyzed in the same
assay.19 3H-NE concentrations were determined
by liquid scintillation counting of radiolabeled
catecholamines after alumina extraction.20
Compartmental analysis of NE kinetics was per-
formed using the two-compartment model as
described by Linares and colleagues.21 Mathematic
modeling was performed using the simulation,
analysis, and modeling (SAAM29) and conversa-
tional simulation, analysis, and modeling (CONSAM)
programs.22,23 The modeling involves determining
a simultaneous fit of all the plasma NE and 3H-NE
data by solving differential equations for both the
endogenous tracee (plasma NE) and tracer (3H-NE)
system by the method of weighted nonlinear least
squares. Parameters that are estimated by SAAM29
are the fractional transfer coefficients (Lij), the vol-
ume of distribution of NE in compartment 1 (VD1,
L), and the steady-state input rate into compart-
ment 2 (NE2, lg ⁄min). Additional measures include
the mass of NE in each compartment, the flux rates
of NE between compartments, and the metabolic
clearance rate of NE from plasma-containing com-
partment. Calculation of the rate of NE appearance
into plasma and the rate of NE clearance from
plasma was by the isotope dilution technique.24
Statistical Analysis
All values are mean  standard error. Weekly BPs,
heart rates, and body weights were determined by
averaging the daily values for each week. Plasma
glucose and insulin were determined by averaging
the two values that were obtained each week. Since
we have previously demonstrated in dogs fed a
high-fat diet that hepatic glucose output was com-
pletely suppressed at an insulin infusion rate of
>1 mU ⁄ (kg ⁄min), the amount of glucose required
to maintain euglycemia during the last 30 minutes
of each insulin infusion was used as the index of
whole-body glucose uptake.18 In an attempt to
measure whole-body glucose uptake independent of
the degree of obesity, some investigators have
indexed whole-body glucose uptake to lean body
mass as opposed to total body weight.25 In the cur-
rent study, since we did not measure lean body
mass in our dogs because we have previously dem-
onstrated that within 3 weeks of stopping the fat
diet the dogs returned to their pre-fat diet weight,26
and because the dogs were fully mature and did
not change their height or length during the
6 weeks of the high-fat diet, we felt that the pre-fat
diet weight was a reasonable surrogate for lean
body mass. Therefore, we expressed whole-body
glucose as glucose per kilogram of pre-fat diet
weight per minute (MPRF).
A mixed model repeated-measures analysis of
variance was performed for each variable to deter-
mine whether a significant change in the variable
occurred over time. A paired t test was used to
determine whether significant differences were
present between the 3 time periods (before and
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after 1 and 6 weeks of the high-fat diet). Due
to the multiple comparisons made in these paired
t tests, a Bonferroni correction was made such
that a P<.025 rather than a P<.05 was used to
document a significant difference between the time
periods.
Linear regression analysis was used to evaluate
whether a relation existed between sympathetic
activation and the development of insulin resistance
and hypertension.
All of the statistical analyses were performed
using SAS software programs (SAS Institute,
Cary, NC).
RESULTS
Hemodynamic and Hormonal Results
During the 6 weeks of the high-fat diet, the dogs
significantly increased their body weight from
22.41.5 to 29.80.7 kg (P<.001) (Table I). The
gain in weight was associated with a significant
increase in mean arterial BP (P<.001) and heart
rate (P<.001). Plasma glucose concentration did
not significantly increase with the high-fat diet.
However, there was a significant increase in fasting
insulin concentration (78.13.1 pmol ⁄L to 2197.1
pmol ⁄L; P<.001). Plasma epinephrine concentration
significantly decreased from 230.124.8 pg ⁄mL to
14.128.4 pg ⁄mL (P<.02) during the 6 weeks of
the fat diet.
Euglycemic Clamp Data
During the euglycemic clamp studies, the steady
state blood glucose concentration averaged approxi-
mately5.3 mm and did not differ from the fasting
concentration prior to the insulin infusion. The
coefficient of variation of glucose level at the insu-
lin plateau was <5%. Feeding the dogs the high-fat
diet was associated with a significant reduction in
insulin-mediated glucose uptake (P<.001) (Table I).
The reduction in insulin-mediated glucose uptake
(MPRF) was apparent within the first week of start-
ing the high-fat diet.
NE Kinetics
During the 6 weeks of the high-fat diet, the dogs
tended to increase their plasma NE concentration
from 24116 pg ⁄mL to 28527 pg ⁄mL (P=.094).
We used a two-compartment model to evaluate the
kinetics of distribution and metabolism of NE
before and during the development of weight
gain.21 Table II summarizes the changes in NE
kinetics that occurred when the dogs were fed a
high-fat diet. Within 1 week of starting the fat diet,
NE release into the extravascular compartment
(NE2) increased from3.440.59 lg ⁄mLto4.870.80
lg ⁄mL and this increase was maintained over the
next 5 weeks of the high-fat diet (NE2 at week 6 was
4.660.97 lg ⁄mL). We also observed that within
1 week of starting the fat diet that NE metabolic
Table I. Hemodynamic, Hormonal, and Euglycemic Clamp Changes Associated With 6 Weeks of a High-Fat Diet
Week 0 Week 1 Week 6


















































Values are expressed as mean  standard error. Abbreviations: MPRF,whole body glucose uptake during a euglycemic clamp
(indexed to pre-fat diet weight); Week 0, before starting the high-fat diet; Week 1, after 1 week of high-fat diet; Week 6, after
6 weeks of the high-fat diet. aSignificant difference P<.05 week 1 vs week 0. bSignificant difference P<.01 week 1 vs week 0.
cSignificant difference P<.01 week 6 vs week 0. dSignificant difference P<.05 week 6 vs week 0. eSignificant difference P<.01
week 6 vs week 1.
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clearance rate (MRC1) also increased from
1.580.11 mL ⁄min to 2.490.51 mL ⁄min and this
increase was also maintained during the next
5 weeks of the fat diet. The increase in MRC1 was
associated with a significant increase in the volume
of distribution of NE in the intravascular compart-
ment (VD1) (VD1 increased from 1.370.27 L to
2.410.57 L [P=.02] after 6 weeks of the high-fat
diet). With weight gain, there was a small increase in
the mass of NE in compartment 1 (Q1) and no signif-
icant increase in the mass of NE in compartment 2
(Q2). There was over 80% more NE mass exchanged
between Q1 and Q2 after 6 weeks of the high-fat diet
(rate of NE appearance into the intravascular com-
partment [R12] 0.4260.047 lg ⁄min to 0.7850.112
lg ⁄min; P=.036). There were no significant differ-
ences in NE spillover faction (SF%) or in the fraction
transport rate coefficients (Lij).
Calculations based on the isotope dilution
method demonstrated that both noncompartmental
NE appearance rate into plasma (NEAP) (P=.021)
and noncompartmental NE clearance from the
plasma (NECL) (P=.039) increased with the high-
fat diet (Table II). R12 is the parameter of the two-
compartment model that is most analogous to
NEAP, and tended to be similar in magnitude
to NEAP both before and after the high-fat diet.
NEAP was much less than NE2 both before and
after the high-fat diet. NECL and MRC1 were
similar in magnitude both before and after the
high-fat diet.
We also observed a significant correlation
between the increase in NE2 (DNE2) and both the
increase in whole-body insulin-mediated glucose
uptake (DMPRF) and the increase in mean arterial
pressure (DBP) (Figure 1 and Figure 2). However,
unlike the relationship between DNE2 and DMPRF,
which was present after both 1 and 6 weeks of
receiving the high-fat diet, the DBP was significantly
related to the increase in NE2 only after the dogs
had been on the high-fat diet for 6 weeks.
DISCUSSION
The results from the current study provide evidence
to support the hypothesis that weight gain induced
by feeding dogs a high-fat diet is associated with
altered whole-body NE kinetics. In addition, these
results also suggest that the rate of NE release into
Table II. Changes in Norepinephrine Kinetic Variables Associated With 6 Weeks of a High-Fat Diet
Week 0 Week 1 Week 6
Dogs 8 7 8 P Value































































Values are expressed as mean  standard error. Abbreviations: MRC1, norepinephrine clearance rate from the intravascular
compartment; NE, plasma norepinephrine; NE2, norepinephrine release into the extravascular compartment; NEAP,
noncompartmental norepinephrine appearance rate in plasma; NECl, noncompartmental norepinephrine clearance form plasma;
Q1, norepinephrine mass in the intravascular compartment; Q2, norepinephrine mass in the extravascular compartment; R12,
rate of norepinephrine appearance into the intravascular compartment; VD1, volume of distribution of norepinephrine in the
intravascular compartment; Week 0, before starting the high-fat diet; week 1, after 1 week of high-fat diet; Week 6, after
6 weeks of the high-fat diet. aSignificant difference P<.05 week 6 vs week 0. bSignificant difference P<.01 week 6 vs week 0.
cSignificant difference P<.01 week 1 vs week 0.
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the extravascular compartment correlates with both
the development of insulin resistance and hyperten-
sion in the high fat–fed dog model of obesity.
The role of enhanced sympathetic activity in the
pathogenesis of obesity hypertension and insulin
resistance remains controversial. A significant com-
ponent of this controversy is related both to the
fact that few studies have serially followed changes
in sympathetic activity in the same animal or indi-
vidual as they gain weight and to limitations in the
methods used to assess sympathetic activity.
There have been few studies that have longitudi-
nally evaluated SNS activity prior to and after the
development of obesity. Katzeff and colleagues15
measured the thermogenic and hormonal responses
to NE during overnutrition and undernutrition in
6 lean and 6 overweight male volunteers. These
investigators demonstrated that both lean and obese
individuals increased their plasma NE concentration
with overfeeding. Gentile and colleagues16 demon-
strated that overfeeding 12 nonobese male volun-
teers resulted in an increase in muscle sympathetic
neural activity and that the change in muscle sym-
pathetic nerve activity burst frequency correlated
with the percent increase in body weight, change in
body fat, and percent change in body fat. Gentile
did not measure the change in NE kinetics with
overfeeding.
Plasma NE levels provide an indirect assessment
of systemic sympathetic activity, since they reflect
the net balance between NE appearance and
removal mechanisms and provide no information
concerning what happens to NE after it is released
from presynaptic sympathetic nerve terminals. NE
kinetic studies using isotope dilution methods
were developed to estimate systemic rates of NE
Figure 1. (A) The regression relationship between the change in NE release into the extravascular compartment
(DNE2) after 1 week of the high fat diet and the change in insulin mediated glucose uptake (D MPRF) in mg glucose
per kg of pre-fat body weight per min. The data from the seven animals that had week 1 measurements made are
shown. (B) The regression relationship between the change in NE release into the extravascular compartment (DNE2)
after 6 weeks of the high fat diet and the change in insulin mediated [2 mU ⁄ (kg min)] glucose uptake (D MPRF) in mg
glucose per kg of pre-fat body weight per min. The data from all eight animals that had week six measurements made
are shown.
Figure 2. (A) The regression relationship between the change in NE release into the extravascular compartment
(DNE2) after 1 week of the high fat diet and the change in mean arterial pressure (DBP). The data from the seven
animals that had week 1 measurements made are shown. (B) The regression relationship between the change in NE
release into the extravascular compartment (DNE2) after 6 weeks of the high fat diet and the change in mean arterial
pressure (DBP). The data from all eight animals that had week six measurements made are shown.
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appearance into and NE clearance from the
plasma. Using this methodology, Coppack and
colleagues8 and Eikelis and colleagues27 found that
compared with lean individuals, obese individuals
had slightly higher spillover rates but the differences
were not significant. In addition, Bazelmans and
colleagues28 found marginally lower systemic NE
spillover rates in obese compared with lean sub-
jects, whereas one other study29 found a direct
positive correlation between adiposity and systemic
NE spillover. In the current study we demonstrated
during 6 weeks of feeding dogs a high-fat diet that,
although plasma NE concentration trended towards
increasing (P=.09), systemic sympathetic activity
assessed by NE kinetic studies significantly
increased (P=.009). Using both a single compart-
ment model and a minimal two-compartment
model21 we demonstrated that within 1 week of
starting the high-fat diet, there was a significant
increase in both NEAP (single-compartment model)
and NE2 (two-compartment model) and that this
increase was maintained during the next 5 weeks
of the fat diet. The most likely reason that we did
not demonstrate a significant increase in plasma
NE levels was because, in addition to the increased
rate of NE release from the sympathetic nerve ter-
minals, we also observed a significant increase in
NE clearance (NECL [single-compartment model]
and MCR1 [two-compartment model]). Compart-
mental analysis demonstrates that the increase in
MCR1 could be explained in large part by the
increase in VD1. It is unlikely that the increase in
NE clearance was primarily due to a change in
uptake1 or uptake2, since we observed only small
changes in the fractional transport rate coefficients
(Lij) of the two-compartment model.
21 Since the
VD1 for NE is known to be somewhat larger than
plasma volume but much less than total extracellu-
lar fluid volume,21 it is not unexpected that VD1
would increase in the high fat–fed dogs since we
and others have demonstrated that this model is
associated with significant fluid retention.26,30,31
The increase in VD1 and the associated increase in
clearance of epinephrine is also the most likely
explanation for the decrease in plasma epinephrine
concentration that was observed during the
6 weeks of the high-fat diet (Table 1). In addition,
the decrease in plasma epinephrine concentration
with the fat diet makes it unlikely that increased
adrenal release of catecholamines was the cause of
the increase in both NEAP and NE2 that occurred
with feeding the dogs the high-fat diet.
The results from this present study also help to
explain the conflicting results from the numerous
cross-sectional studies evaluating the differences in
whole-body SNS activity in lean and obese patients.
As can be seen in Table II, we observed marked
variability in NE kinetics between the 8 animals
that were studied. It was only with our longitudinal
design that we were able to document a significant
increase in whole animal NE release.
The other important finding from the current
study was the association between sympathetic acti-
vation and the development of insulin resistance
and hypertension. In the high fat–fed dog, we previ-
ously reported that insulin resistance occurs within
1 week of starting the high-fat diet.18 In the current
study, we observed both at 1 and 6 weeks of the
high-fat diet a significant correlation between the
increase in NE2 and the decrease in MPRF
(Figure 1). This current finding, along with our
previous findings that clonidine prevents the insulin
resistance associated with dogs fed a high-fat
diet32,33 and the recent report of Chazova and col-
leagues34 demonstrating that moxonidine improves
glycemic control in overweight individuals, are con-
sistent with but do not prove our hypothesis that
increased sympathetic activity is potentially impor-
tant in the pathogenesis of insulin resistance in the
high fat–fed model of obesity.
Unlike insulin resistance, the increase in BP that
occurs with the high-fat diet did not correlate to
the increase in sympathetic activity until the ani-
mals had received 6 weeks of the diet (Figure 2).
This observation is also consistent with our knowl-
edge of BP regulation in this animal model of obes-
ity. We and others have demonstrated that the
hypertension associated with feeding dogs a high-
fat diet is due to chronic sodium retention.26,30 We
also know that the SNS is involved in the hyperten-
sion based on both pharmacologic studies32,33 as
well as the studies of Kassab and colleagues,31
which demonstrated that obesity-induced hyperten-
sion could be prevented by renal sympathetic
denervation. In addition, Vaz and colleagues,9 using
regional analysis of NE kinetics, demonstrated
increased renal NE spillover in obese patients. Since
the renal sympathetic–mediated fluid retention takes
weeks to fully develop, it is not surprising that the
significant relation between the increase in NE2 and
increase in mean arterial pressure did not become
evident until week 6 of the high-fat diet.
CONCLUSIONS
We observed that when dogs are fed a high-fat diet
there is both a significant increase in NE release
from sympathetic nerve terminals and an increase
in the metabolic clearance of NE from the plasma.
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In addition, this increase in sympathetic activity
correlates with both the development of insulin
resistance and hypertension.
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